FrancophonIA/ELRC3.0 huggingface dataset:
English: You must not use the bottle if the tamper-proof seal on the bottle neck is broken before you first use it.
Croatian: Bočicu ne smijete koristiti ako je prije prve primjene sigurnosna folija na vratu bočice oštećena.
English: Effects in non-clinical studies were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use.
Croatian: U nekliničkim ispitivanjima zapaženi su učinci samo pri izloženosti dozama koje su znatno veće od maksimalno dozvoljenih u ljudi, što ukazuje na njihov mali značaj za kliničku primjenu.
English: The elimination half-life, determined after intravenous administration, was approximately 45 minutes; the total blood clearance was 1.5 l/hr/kg.
Croatian: Poluvrijeme eliminacije, utvrđeno nakon intravenske primjene, bilo je otprilike 45 minuta; ukupni krvni klirens bio je 1,5 l/h/kg.
English: The dose should not exceed once daily, as more frequent administration may lessen the intraocular pressure lowering effect.
Croatian: Doza jedanput dnevno ne smije se prekoračiti jer češća primjena može smanjiti učinak snižavanja intraokularnog tlaka.
English: If you use LUMIGAN with another eye medicine, wait at least five minutes between using LUMIGAN and the other eye medicine.
Croatian: Ako primjenjujete LUMIGAN uz druge lijekove za oko, pričekajte najmanje 5 minuta između primjene kapi LUMIGAN i primjene drugih lijekova za oči.
English: There is a potential for the IOP-lowering effect of prostaglandin analogues (e.g. LUMIGAN) to be reduced in patients with glaucoma or ocular hypertension when used with other prostaglandin analogues (see section 4.4).
Croatian: Postoji mogućnost smanjivanja učinka analoga prostaglandina (npr. LUMIGAN-a) na snižavanje očnog tlaka u bolesnika s glaukomom ili povišenim intraokularnim tlakom kada se koriste s drugim analozima prostaglandina (vidjeti dio 4.4).
English: Other medicines and LUMIGAN 0.3 mg/mL single-dose Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
Croatian: Drugi lijekovi i jednodozni LUMIGAN 0,3 mg/ml Obavijestite svog liječnika ili ljekarnika ako uzimate, nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove.
English: Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts become more brownish.
Croatian: Obično se smeđi pigment širi oko zjenice koncentrično prema periferiji šarenice pa s vremenom čitava šarenica ili neki njezini dijelovi postaju više smeđi.
English: Patients using LUMIGAN with other prostaglandin analogues should be monitored for changes to their intraocular pressure.
Croatian: U bolesnika koji koriste LUMIGAN s drugim analozima prostaglandina potrebno je nadzirati promjene njihovog očnog tlaka.
English: Wait 15 minutes after using the drops, and before you put your lenses back in.
Croatian: Pričekajte 15 minuta nakon što se stavili kapi prije nego leće vratite u oko.
English: Periorbital tissue pigmentation has been reported to be reversible in some patients.
Croatian: Pigmentacija tkiva oko oka prijavljena je kao reverzibilna kod nekih bolesnika.
English: Iris colour changes seen with ophthalmic administration of bimatoprost may not be noticeable for several months to years.
Croatian: Promjene boje šarenice koje se javljaju pri oftamološkoj primjeni bimatoprosta mogu ostati nezamijećene nekoliko mjeseci do godina.
English: LUMIGAN should be used with caution in patients predisposed to low heart rate or low blood pressure.
Croatian: LUMIGAN je potrebno primjenjivati s oprezom kod bolesnika s predispozicijom za spore otkucaje srca ili nizak krvni tlak.
English: The mechanism of action by which bimatoprost reduces intraocular pressure in humans is by increasing aqueous humour outflow through the trabecular meshwork and enhancing uveoscleral outflow.
Croatian: Mehanizam djelovanja kojim bimatoprost snižava intraokularni tlak u ljudi je povećanje istjecanja očne vodice kroz trabekularno tkivo i poboljšanje uveoskleralnog istjecanja.
English: • Cystoid macular oedema (swelling of the retina within the eye leading to worsening vision)
Croatian: • Cistoidni makularni edem (oticanje mrežnice u oku što dovodi do pogoršanja vida)
English: Possible side effects Like all medicines, this medicine can cause side effects, although not everybody gets them.
Croatian: Moguće nuspojave Kao i svi drugi lijekovi, ovaj lijek može uzrokovati nuspojave iako se one neće javiti kod svakoga.
English: This medicinal product does not require any special storage conditions.
Croatian: Lijek ne zahtijeva posebne uvjete čuvanja.
English: Turn the bottle upside down and squeeze it to release one drop into each eye that needs treatment.
Croatian: Postavite bočicu naopako i lagano istisnite jednu kap u svako oko koje treba liječiti.
English: Bimatoprost is moderately distributed into body tissues and the systemic volume of distribution in humans at steady-state was 0.67 l/kg.
Croatian: Bimatoprost se umjereno distribuira u tjelesnim tkivima te je sistemski volumen distribucije u ljudi u stanju dinamičke ravnoteže iznosio 0,67 l/kg.
English: Most were ocular, mild to moderate, and none was serious: With each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Croatian: Većina njih se pojavila u očima; bile su blage do umjerene, a nijedna ozbiljne prirode: Unutar svake skupine učestalosti, nuspojave su prikazane redoslijedom od ozbiljnijih prema manje ozbiljnima.
English: Approximately 4 % of patients discontinued due to any adverse event in the 12-month study.
Croatian: Približno 4% bolesnika prekinulo je terapiju zbog neke nuspojave u 12-mjesečnom ispitivanju.
English: • Worsening vision
Croatian: • Pogoršanje vida
English: • Dry skin
Croatian: • Suha koža
English: The solution should be used immediately after opening.
Croatian: Otopinu treba primijeniti neposredno nakon otvaranja.
English: 10 single-dose containers
Croatian: 10 jednodoznih spremnika
English: This leaflet is available in all EU/EEA languages on the European Medicines Agency we
Croatian: Ova uputa o lijeku dostupna je na svim jezicima EU-a/EGP-a na internetskim stranicama Europske agencije za lijekove.
English: LUMIGAN is used to reduce high pressure in the eye.
Croatian: LUMIGAN se koristi za sniženje visokog očnog tlaka.
English: If you stop using LUMIGAN 0.3 mg/mL single-dose the pressure inside your eye may go up, therefore talk to your doctor before stopping this treatment.
Croatian: Ako prestanete primjenjivati jednodozni LUMIGAN 0,3 mg/ml, tlak u oku bi Vam mogao porasti, stoga razgovarajte sa svojim liječnikom prije prekida liječenja.
English: Investigations common liver function test abnormal
Croatian: Pretrage često abnormalni rezultati pretraga funkcije jetre
English: LUMIGAN should be used with caution in patients with a prior history of significant ocular viral infections (e.g. herpes simplex) or uveitis/iritis.
Croatian: LUMIGAN treba koristiti s oprezom kod bolesnika s anamnezom značajnih virusnih infekcija oka (npr. herpes simpleks) ili uveitisa/iritisa.
English: • Hair growth around the eye
Croatian: • Rast dlaka oko oka
English: Wash your hands before use.
Croatian: Prije primjene morate oprati ruke.
English: • Eyes appear sunken
Croatian: • Oči izgledaju utisnute
English: There have been reports of bacterial keratitis associated with the use of multiple dose containers of topical ophthalmic products.
Croatian: Prijavljeni su slučajevi bakterijskih keratitisa povezanih s korištenjem višedoznih spremnika topikalnih oftalmičkih pripravaka.
English: To avoid contamination, do not let the open-end of the single-dose container touch your eye or anything else.
Croatian: Kako biste spriječili kontaminaciju, nemojte otvorenim vrhom jednodoznog spremnika doticati oko niti bilo koju drugu površinu.
English: Clinical efficacy
Croatian: Klinička djelotvornost i sigurnost
English: Bimatoprost is biotransformed by any of multiple enzymes and pathways, and no effects on hepatic drug metabolising enzymes were observed in preclinical studies.
Croatian: Bimatoprost se biotransformira preko mnogih enzima i raznih putova razgradnje; u nekliničkim ispitivanjima nisu zabilježeni učinci na jetrene enzime koji metaboliziraju lijekove.
English: It is unknown whether bimatoprost is excreted in human breast milk.
Croatian: Nije poznato izlučuje li se bimatoprost u majčino mlijeko.
English: The most frequently reported adverse reaction was conjunctival hyperaemia (mostly trace to mild and of a non-inflammatory nature) occurring in 29 % of patients.
Croatian: Najčešća prijavljena nuspojava bila je hiperemija konjunktive (uglavnom u tragovima ili u blagom obliku i neupalne prirode), i to u 29% bolesnika.
English: No information is available on overdose in humans; overdose is unlikely to occur after ocular administration.
Croatian: Nema dostupnih podataka o predoziranju u ljudi, nije vjerojatno da predoziranje može nastupiti nakon okularne primjene.
English: Before treatment is initiated, patients should be informed of the possibility of eyelash growth, darkening of the eyelid skin and increased iris pigmentation, since these have been observed during treatment with LUMIGAN.
Croatian: Prije početka liječenja, treba informirati bolesnike o mogućnosti rasta trepavica, tamnjenja kože vjeđa i povećane pigmentacije šarenice, jer su te promjene opažene tijekom liječenja kapima LUMIGAN.
English: LUMIGAN 0.3 mg/mL single-dose may get into breast milk so you should not breast-feed while you are taking this medicine.
Croatian: Jednodozni LUMIGAN 0,3 mg/ml može dospjeti u mlijeko dojilja stoga ne smijete dojiti dok uzimate ovaj lijek.
English: Table 2.
Croatian: Tablica 2.
English: - If you have further questions, ask your doctor or pharmacist.
Croatian: - Ako imate dodatnih pitanja, obratite se liječniku ili ljekarniku.
English: Discard 4 weeks after first opening Exp:
Croatian: ROK VALJANOSTI Bacite 4 tjedna nakon prvog otvaranja Exp:
English: • Weakness
Croatian: • Slabost
English: In embryo/foetal developmental studies abortion, but no developmental effects were seen in mice and rats at doses that were at least 860-times or 1700-times higher than the dose in humans, respectively.
Croatian: U ispitivanjima embrionalnog/fetalnog razvoja u miševa i štakora zapaženi su pobačaji, ali ne i poremećaji razvoja ploda, pri dozama koje su bile barem 860 odnosno 1700 puta veće od doze u ljudi.
English: Since LUMIGAN contains benzalkonium chloride, monitoring is required with frequent or prolonged use in dry eye patients or where the cornea is compromised.
Croatian: Budući da LUMIGAN sadrži benzalkonijev klorid, potrebno je pratiti bolesnike sa suhim očima ili oštećenom rožnicom koji često ili duže vremena koriste LUMIGAN.
English: The most frequently reported adverse reactions were conjuctival hyperaemia (mostly trace to mild and of a non-inflammatory nature) occurring in 24% of patients, and eye pruritis occurring in 4% of patients.
Croatian: Najčešća prijavljena nuspojava bila je hiperemija konjunktive (uglavnom u tragovima ili u blagom obliku i neupalne prirode), i to u 24% bolesnika, a svrbež oka u 4% bolesnika.
English: LUMIGAN 0.3 mg/mL single-dose has not been tested in children under the age of 18 and therefore should not be used by patients under 18 years.
Croatian: Jednodozni LUMIGAN 0,3 mg/ml nije ispitivan kod djece do 18 godina i stoga se ne smije koristiti kod bolesnika mlađih od 18 godina.
English: Contact lenses should be removed prior to instillation and may be reinserted 15 minutes following administration.
Croatian: Prije primjene, potrebno je ukloniti kontaktne leće i pričekati najmanje 15 minuta nakon primjene prije njihovog ponovnog umetanja.
English: The recommended dose is one drop in the affected eye(s) once daily, administered in the evening.
Croatian: Preporučena doza je jedna kap u zahvaćeno oko (oči) jedanput dnevno, primijenjena navečer.
English: If you use LUMIGAN 0.3 mg/mL single-dose with another eye medicine, wait at least 5 minutes between using LUMIGAN 0.3 mg/mL single-dose and the other eye medicine.
Croatian: Ako primjenjujete jednodozni LUMIGAN 0,3 mg/ml uz druge lijekove za oko, pričekajte najmanje 5 minuta između primjene kapi jednodoznog LUMIGAN-a 0,3 mg/ml i primjene drugih lijekova za oči.
English: Affecting the body
Croatian: Na razini tijela
English: Opened (1):
Croatian: Otvoreno (1):
English: Discard the opened single-dose container immediately after use.
Croatian: Otvoreni jednodozni spremnik bacite odmah nakon uporabe.
English: Since LUMIGAN 0.1 mg/ml contains 200 ppm benzalkonium chloride (four times the concentration in bimatoprost 0.3 mg/ml eye drops), it should be used with caution in dry eye patients, in patients where the cornea may be compromised and in patients taking multiple BAK-containing eye drops.
Croatian: Budući da LUMIGAN 0,1 mg/ml sadrži 200 ppm benzalkonijevog klorida (četiri puta veća koncentracija nego u kapima za oko bimatoprost 0,3 mg/ml), potrebno ga je primjenjivati s oprezom kod bolesnika sa suhim očima ili s mogućim oštećenjem rožnice te kod bolesnika koji uzimaju više različitih kapi za oko koje sadrže benzalkonijev klorid.
English: Pack contains 3 or 9 aluminium foil pouches, each containing 10 single-dose containers, for a total of 30 or 90 single-dose containers in a carton, respectively.
Croatian: Pakiranje sadrži 3 ili 9 vrećica od aluminijske folije, svaka vrećica sadrži 10 jednodoznih spremnika s ukupno 30 odnosno 90 jednodoznih spremnika u kutiji.
English: Opened (2):
Croatian: Otvoreno (2):
English: Therefore, LUMIGAN should be used with caution in patients with known risk factors for macular oedema (e.g. aphakic patients, pseudophakic patients with a torn posterior lens capsule).
Croatian: Stoga LUMIGAN treba koristiti s oprezom kod bolesnika s poznatim čimbenicima rizika za razvoj makularnog edema (npr. bolesnici s afakijom, pseudofakijom s pokidanom stražnjom kapsulom leće).
English: Pack contains 5-single-dose containers in a carton.
Croatian: Pakiranje sadrži 5 jednodoznih spremnika u kutiji.
English: Opened (3):
Croatian: Otvoreno (3):
English: LUMIGAN 0.3 mg/mL single-dose eye drops are used to reduce high pressure in the eye.
Croatian: Jednodozni LUMIGAN 0,3 mg/ml koristi se za sniženje visokog očnog tlaka.
English: Bimatoprost did not impair fertility in rats up to doses of 0.6 mg/kg/day (at least 103-times the intended human exposure).
Croatian: Bimatoprost nije izazvao oštećenje plodnosti u štakora u dozama do 0,6 mg/kg/dan (što je najmanje 103 puta namjeravana izloženost u ljudi).
English: These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent ocular disease.
Croatian: Te su spremnike nehotice kontaminirali sami bolesnici koji su imali istodobnu očnu bolest.
English: This dose is at least 22 times higher than an accidental dose of the entire content of a pack of LUMIGAN 0.3 mg/mL single-dose (30 x 0.4 mL single-dose containers; 12 mL) in a 10 kg child.
Croatian: Ova doza je najmanje 22 puta viša od nehotično uzete doze jednog cijelog pakiranja pojedinačnih doza otopine LUMIGAN 0,3 mg/ml (30 jednodoznih spremnika od 0,4 ml, ukupno 12 ml) u djeteta od 10 kg.
English: EXP Once the pouch is opened, the single dose containers should be used within 30 days.
Croatian: EXP Nakon što se vrećica otvori, jednodozne spremnike treba upotrijebiti unutar 30 dana.
English: • Darker skin colour around the eye
Croatian: • Tamnija boja kože oko oka
English: LUMIGAN 0.1 mg/ml contains the preservative benzalkonium chloride (200 ppm), which may be absorbed by soft contact lenses.
Croatian: LUMIGAN 0,1 mg/ml sadrži konzervans benzalkonijev klorid (200 ppm), koji bi mogle apsorbirati mekane kontaktne leće.
English: LUMIGAN 0.3 mg/mL single-dose also achieved equivalent IOP lowering efficacy with LUMIGAN 0.3 mg/mL (multi-dose formulation) in average eye IOP at each follow-up timepoint at weeks 2, 6 and 12.
Croatian: Jednodozni LUMIGAN 0,3 mg/ml bio je jednako djelotvoran u snižavanju intraokularnog tlaka kao i LUMIGAN 0,3 mg/ml (višedozni pripravak) pri svakom kontrolnom mjerenju u vremenskim točkama nakon 2, 6 i 12 tjedana.
English: In addition to the side effects for LUMIGAN 0.1 mg/ml, the following side effects have been seen with another medicine containing a higher strength of bimatoprost (0.3 mg/ml):
Croatian: Osim nuspojava kapi LUMIGAN 0,1 mg/ml, sljedeće nuspojave opažene su kod drugog lijeka koji sadrži veću jačinu bimatoprosta (0,3 mg/ml):
English: Colourless solution.
Croatian: Bezbojna otopina.
English: Monkeys administered ocular bimatoprost concentrations of 0.3 mg/mL daily for 1 year had an increase in iris pigmentation and reversible dose-related periocular effects characterised by a prominent upper and/or lower sulcus and widening of the palpebral fissure.
Croatian: Majmuni kojima su u oko davane koncentracije bimatoprosta od 0,3 mg/ml dnevno tijekom 1 godine imali su povećanu pigmentaciju šarenice i reverzibilne, s dozom povezane periokularne učinke karakterizirane prominentnim gornjim i/ili donjim sulkusom i proširenjem palpebralne fisure.
English: LUMIGAN may cause your eyelashes to darken and grow, and cause the skin around the eyelid to darken too.
Croatian: LUMIGAN može prouzročiti tamnjenje i rast trepavica te tamnjenje kože oko vjeđe.
English: Vascular disorders not known hypertension
Croatian: Krvožilni poremećaji nepoznato hipertenzija
English: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from available data) adverse reactions are presented according to System Organ Class in Table 1.
Croatian: Nuspojave u Tablici 1 navedene su prema klasifikaciji organskih sustava i sljedećim kategorijama učestalosti: vrlo često (≥ 1/10); često (≥1/100 do <1/10); manje često (≥1/1000 do <1/100); rijetko (≥1/10 000 do <1/1000); vrlo rijetko (<1/10 000); nepoznato (ne može se procijeniti iz dostupnih podataka).
English: Hypersensitivity reaction including signs and symptoms of eye allergy and allergic dermatitis
Croatian: Poremećaji imunološkog sustava nepoznato reakcija preosjetljivosti uključujući znakove i simptome očne alergije i alergijskog dermatitisa
English: Do not use this medicine after the expiry date which is stated on the bottle label and the carton after EXP.
Croatian: Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na naljepnici bočice i kutiji iza oznake EXP.
English: The recommended dose is one drop of LUMIGAN in the evening, once daily in each eye that needs treatment.
Croatian: Preporučena doza je jedna kap otopine LUMIGAN navečer, jedanput dnevno u svako oko koje treba liječiti.
English: Other side effects reported with eye drops containing phosphates.
Croatian: Druge nuspojave prijavljene pri primjeni kapi za oči koje sadrže fosfate.
English: Skin and subcutaneous tissue disorders not known periobital erythema
Croatian: Poremećaji kože i potkožnog tkiva nepoznato periorbitalni eritem
English: No clinically relevant effects on heart rate and blood pressure have been observed in clinical trials.
Croatian: U kliničkim ispitivanjima nisu zabilježeni klinički relevantni učinci na brzinu otkucaja srca i krvni tlak.
English: While there is limited information available on patients with a history of asthma or COPD, there have been reports of exacerbation of asthma, dyspnoea and COPD, as well as reports of asthma, in post marketing experience.
Croatian: Iako su dostupni podaci o bolesnicima s astmom i KOPB-om u anamnezi ograničeni, postoje izvješća o egzacerbaciji astme, dispneje i KOBP-a, kao i izvješća o astmi nakon što je lijek stavljen u promet.
English: If the liquid cannot drain out quickly enough, the pressure inside the eye builds up.
Croatian: Ako se oko puni tekućinom brže nego što ona istječe, dolazi do porasta tlaka u oku.
English: LUMIGAN has not been tested in children under the age of 18 and therefore should not be used by patients under 18 years.
Croatian: LUMIGAN nije ispitivan kod djece do 18 godina i stoga se ne smije koristiti kod bolesnika mlađih od 18 godina.
English: LUMIGAN eye drops are used to reduce high pressure in the eye.
Croatian: LUMIGAN kapi za oko koriste se za sniženje visokog očnog tlaka.
English: LUMIGAN has not been studied in patients with renal or moderate to severe hepatic impairment and should therefore be used with caution in such patients.
Croatian: LUMIGAN nije ispitivan na bolesnicima s bubrežnim ili umjerenim do teškim jetrenim oštećenjem i stoga se treba primjenjivati s oprezom kod tih bolesnika.
English: Throw away the single-dose container after you have used it, even if there is some solution left.
Croatian: Nakon primjene bacite jednodozni spremnik čak i ako je u njemu ostalo još nešto otopine.
English: The recommended dose is one drop once daily, in the evening, once daily in each eye that needs treatment.
Croatian: Preporučena doza je jedna kap otopine navečer, jedanput dnevno u svako oko koje treba liječiti.
English: No interactions are anticipated in humans, since systemic concentrations of bimatoprost are extremely low (less than 0.2 ng/ml) following ocular dosing with bimatoprost 0.3 mg/ml eye drops, solution.
Croatian: Interakcije se ne očekuju kod ljudi jer su sistemske koncentracije bimatoprosta izuzetno niske (manje od 0,2 ng/ml) nakon okularne primjene otopine bimatoprost 0,3 mg/ml kapi za oko.
English: If you forget to use LUMIGAN 0.3 mg/mL single-dose If you forget to use this medicine, use a single drop as soon as you remember, and then go back to your regular routine.
Croatian: Ako ste zaboravili primijeniti jednodozni LUMIGAN 0,3 mg/ml Ako zaboravite primijeniti ovaj lijek, primijenite jednu kap čim se sjetite, a nakon toga se vratite uobičajenoj rutini.
English: uncommon hair growth abnormal not known skin discoloration (periocular)
Croatian: manje često abnormalni rast dlaka nepoznato diskoloracija kože (periokularno)
English: A 12 week (double-masked, randomized, parallel group ) clinical study compared the efficacy and safety of LUMIGAN 0.3 mg/mL single-dose with LUMIGAN 0.3 mg/mL (multi-dose formulation).
Croatian: U 12-tjednom dvostruko slijepom, randomiziranom, paralelnom kliničkom ispitivanju uspoređivala se djelotvornost i sigurnost primjene otopine jednodoznog LUMIGAN-a 0,3 mg/ml s otopinom LUMIGAN 0,3 mg/ml (višedoznog pripravka).
English: Make sure that the single-dose container is intact before use.
Croatian: Provjerite prije primjene da jednodozni spremnik nije oštećen.
English: Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Croatian: Unutar svake skupine učestalosti, nuspojave su prikazane redoslijedom od ozbiljnijih prema manje ozbiljnima.
English: LUMIGAN has not been tested in children under the age of 18 and therefore LUMIGAN should not be used by patients under 18 years.
Croatian: LUMIGAN nije ispitivan kod djece do 18 godina i stoga se LUMIGAN ne smije koristiti kod bolesnika mlađih od 18 godina.
English: In patients with a history of mild liver disease or abnormal alanine aminotransferase (ALT), aspartate aminotransferase (AST) and/or bilirubin at baseline, bimatoprost 0.3 mg/ml eye drops, solution had no adverse effect on liver function over 24 months.
Croatian: Kod bolesnika s anamnezom blage jetrene bolesti ili abnormalne razine alanin-aminotransferaze (ALT), aspartat-aminotransferaze (AST) i/ili bilirubina na početku liječenja, otopina bimatoprost 0,3 mg/ml kapi za oko nije imala štetni učinak na funkciju jetre tijekom 24 mjeseca.
English: At any visit, the mean diurnal IOP values measured over the 12-month study period differed by no more than 1.3 mmHg throughout the day and were never greater than 18.0 mmHg.
Croatian: Pri svakom pregledu, srednje dnevne vrijednosti intraokularnog tlaka izmjerene u razdoblju 12-mjesečnog ispitivanja razlikovale su se najviše 1,3 mmHg kroz dan i nikada nisu bile veće od 18,0 mmHg.